OPT-822

Globo H-KLH · OBI Pharma, Inc

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OPT-822, covering 2020-09-16 to 2020-09-16. Get the full timeline:

Most recent: Clinical Trial Update: Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects [Phase 2]